Earnings Summary

Forma Therapeutics Holdings Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Forma Therapeutics Holdings Inc has generated NaN% jump in its revenue since last 3-months.

Forma Therapeutics Holdings Inc’s net profit fell -22.8% since last year same period to $-44.16Mn in the Q1 2022. On a quarterly growth basis, Forma Therapeutics Holdings Inc has generated 11.9% jump in its net profits since last 3-months.

Forma Therapeutics Holdings Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Forma Therapeutics Holdings Inc has generated NaN% jump in its net profit margins since last 3-months.

Forma Therapeutics Holdings Inc’s earning per share (EPS) estimates for the current quarter stand at -0.99 - a 5.71% jump from last quarter’s estimates.

Forma Therapeutics Holdings Inc’s earning per share (EPS) estimates for the current year stand at -0.99.

Forma Therapeutics Holdings Inc’s earning per share (EPS) fell -22.37% since last year same period to -0.93 in the Q1 2022. This indicates that the Forma Therapeutics Holdings Inc has generated -22.37% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Forma Therapeutics Holdings Inc’s return on assets (ROA) stands at -0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Forma Therapeutics Holdings Inc’s return on equity (ROE) stands at -0.38.